Shouyao Holdings Co Ltd is a China-based company mainly engaged in the discovery and development of innovative small molecule therapies in the field of cancer. The Company's independently developed product pipeline mainly includes SY-707, SY-3505, SY-5007, SY-5933, SY-4798, SY-4835, SY-9453, SY-7166, SY-12321, and SY-14556. The company's collaborative developed product pipeline mainly includes CT-1139/TQ-B3139, CT-1995/TQ05105, CT-2755/TQ-B3454, CT-034/TQ-B3234, CT-2426/TQ-B3455, CT-133/CSPCHA115, CT-1495/TQ-B3395, CT-1803/TQ-B3303, CT-3417/TQ-B3558, CT-3872/TQ-B3811 and CT-4460/TQ-B3617. The Company operates its businesses in the domestic market.

Employees

172

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
09/26/09	31.83 ¥	+4.39%	15,22,757
08/26/08	30.49 ¥	-8.08%	21,53,209
05/26/05	33.17 ¥	-0.66%	10,60,078
04/26/04	33.39 ¥	-3.44%	14,41,800
03/26/03	34.58 ¥	-0.77%	11,06,559

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 09/06/2026			5-day change	1st Jan Change
31.83 ^CNY	+4.39%		-8.67%	-8.38%

17/04	Shouyao Holdings Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Shouyao Holdings Co., LTD. announced that it expects to receive CNY 300 million in funding	CI

Market Cap	473.37Cr 70Cr 60Cr 56Cr 52Cr 97Cr 6.66TCr 99Cr 660.62Cr 256.36Cr 3.22TCr 262.36Cr 256.66Cr 11TCr	P/E ratio 2024	-20.9x	P/E ratio 2025	-39.9x
Enterprise value	407.55Cr 60Cr 52Cr 48Cr 45Cr 84Cr 5.74TCr 85Cr 568.77Cr 220.71Cr 2.77TCr 225.88Cr 220.97Cr 9.64TCr	EV / Sales 2024	935x	EV / Sales 2025	520x
Free-Float	27.12%	Yield 2024 *	-	Yield 2025	-

17/04	Shouyao Holdings Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Shouyao Holdings Co., LTD. announced that it expects to receive CNY 300 million in funding	CI
05/02	Shouyao Holdings Obtains Approval for Cancer Drug Trial	MT
30/01	Shouyao Holdings Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/12	Shouyao Holdings plans to seek Hong Kong listing	RE
30/25/30	Shouyao Holdings Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
27/25/27	Shouyao Holdings Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/25/28	Shouyao Holdings Gets Ethical Approval for Tumor Clinical Trials	MT
27/25/27	Shouyao Holdings Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
17/25/17	Shouyao Holdings Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
27/24/27	Shouyao Holdings Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
25/24/25	Shouyao Holdings Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
28/24/28	Shouyao Holdings Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

1 day	+4.39%
1 week	-8.67%
Current month	-12.99%
1 month	-23.56%
3 months	-17.79%
6 months	-17.75%
Current year	-8.38%

Shouyao Holdings (Beijing) Co., LTD. Share Price

Stocks

688197

CNE1000062V6

Biotechnology & Medical Research

Valuation: Shouyao Holdings (Beijing) Co., LTD.

Chart: Shouyao Holdings (Beijing) Co., LTD.

Latest news : Shouyao Holdings (Beijing) Co., LTD.

Quotes and Performance

Course Extremes

Managers and Directors: Shouyao Holdings (Beijing) Co., LTD.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	30.11	34.69
1 month	30.11	44.92
Current year	30.11	46.25
1 year	30.11	56.86
3 years	25.52	61.63
5 years	17.52	68
10 years	17.52	68

Manager	Title	Age	Since
Wen Jun Li CEO	Chief Executive Officer	59	01/01/2021
Ya Jie Wang DFI	Director of Finance/CFO	56	01/05/2019
Ying Hui Sun CTO	Chief Tech/Sci/R&D Officer	46	01/08/2010

Director	Title	Age	Since
Wen Jun Li CHM	Chairman	59	01/04/2016
Xin He Xu BRD	Director/Board Member	52	01/08/2020
Jing Han Wang CHM	Chairman	37	01/08/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHOUYAO HOLDINGS (BEIJING) CO., LTD.	+4.39%	-8.67%	-26.01%	-38.82%	70Cr
LONZA GROUP AG	+1.23%	-0.22%	-13.62%	-11.99%	4.34TCr
REVOLUTION MEDICINES, INC.	+0.71%	-1.16%	+268.53%	+485.55%	3.18TCr
IQVIA HOLDINGS INC.	+1.39%	+3.11%	+20.82%	-9.85%	3.11TCr
BEONE MEDICINES AG	-0.97%	-2.37%	+1.66%	+24.13%	2.98TCr
CELLTRION, INC.	+6.65%	-5.00%	+11.42%	+15.34%	2.45TCr
EUROFINS SCIENTIFIC SE	+0.15%	+5.93%	+11.00%	+8.63%	1.32TCr
MEDPACE HOLDINGS, INC.	+1.94%	+4.76%	+56.47%	+124.57%	1.33TCr
ASCENDIS PHARMA A/S	+3.61%	-1.56%	-	-	1.32TCr
IONIS PHARMACEUTICALS, INC.	+1.41%	+2.21%	+102.88%	+83.47%	1.23TCr
Average	+2.05%	-0.23%	+48.13%	+75.67%	2.13TCr
Weighted average by Cap.	+1.64%	-0.00%	+55.32%	+92.36%

	2024	2025
Net sales	39.42L 6L 5L 5L 4L 8L 5.55Cr 8L 55.01L 21.35L 2.68Cr 21.85L 21.37L 9.33Cr	86.68L 12.79L 11.07L 10.2L 10L 17.85L 12Cr 18.18L 1.21Cr 46.94L 5.9Cr 48.04L 47L 21Cr
Net income	-21Cr -3.13Cr -2.71Cr -2.49Cr -2.34Cr -4.36Cr -298.3Cr -4.44Cr -30Cr -11Cr -144.27Cr -12Cr -11Cr -501.35Cr	-13Cr -1.9Cr -1.64Cr -1.52Cr -1.42Cr -2.65Cr -181.33Cr -2.7Cr -18Cr -6.98Cr -88Cr -7.14Cr -6.99Cr -304.76Cr
Net Debt	-75Cr -11Cr -9.62Cr -8.87Cr -8.31Cr -16Cr -1.06TCr -16Cr -105.18Cr -41Cr -513.03Cr -42Cr -41Cr -1.78TCr	-66Cr -9.72Cr -8.4Cr -7.74Cr -7.26Cr -14Cr -926.44Cr -14Cr -92Cr -36Cr -448.07Cr -36Cr -36Cr -1.56TCr